We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.15 | -1.29% | 87.70 | 87.45 | 88.85 | 89.65 | 87.45 | 89.06 | 1,576,217 | 02:00:55 |
By Cecilia Butini
Sanofi SA reported earnings on Wednesday. Here is what you need to know.
SALES: Sales fell to 8.59 billion euros ($10.39 billion) for the first quarter, just shy of a consensus estimate provided by FactSet which saw the metric at EUR8.63 billion.
NET PROFIT: Net profit also fell but beat expectations. It came in at EUR1.57 billion, compared with a consensus provided by FactSet which had it at EUR1.26 billion.
WHAT WE WATCHED:
-DUPIXENT AND VACCINES: As expected, eczema drug Dupixent drew growth during the quarter, with sales increasing by 45.6% to EUR1.05 billion, while vaccines and general medicines also had a strong performance. Vaccines were a "good surprise" in 1Q, according to Bryan Garnier analysts, who say that the business was 5% ahead of expectations.
-COVID-19 VACCINE: Phase 2 results for the Covid-19 vaccine which the company is developing together with GlaxoSmithKline PLC are expected next month. Development of the shot had suffered a setback in December, and it isn't expected to be available before the final quarter of the year. Trial results of a phase-3 study to address emerging coronavirus variants are also expected in 2Q.
-GUIDANCE: The outlook for 2021 was reiterated as expected, with Sanofi foreseeing business earnings per share to grow in the high-single digit range at constant exchange rates, barring unforeseen events.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 28, 2021 09:49 ET (13:49 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions